Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence

Autor:	Karin E. Kerfoot, Ellen L. Edens, J. Serrita Jane, Elizabeth Ralevski, Ismene L. Petrakis, Melanie Russo Ba, Kathryn Keegan Rn-Bc, Jane Weiner Rn, Bachaar Arnaout, Erin O’Brien PsyD
Rok vydání:	2013
Předmět:	medicine.medical_specialty biology business.industry Alcohol dependence biology.organism_classification Placebo Psychiatry and Mental health Smok Mecamylamine medicine Dual diagnosis Antidepressant Medical diagnosis Psychiatry business Depression (differential diagnoses) medicine.drug
Zdroj:	Journal of Dual Diagnosis. 9:301-310
ISSN:	1550-4271 1550-4263
DOI:	10.1080/15504263.2013.835163
Popis:	Objective: Currently there is no consensus on the best treatment for individuals with dual diagnoses of alcohol dependence and depression. The aim of this study was to assess the efficacy of mecamylamine augmentation of an antidepressant in reducing drinking, smoking, and depressive symptoms. Methods: This was a double-blind, randomized 12-week treatment trial comparing mecamylamine to placebo. Twenty-one participants with diagnosed alcohol dependence and comorbid depression were included in this study. Eleven participants were assigned to mecamylamine and ten were assigned to placebo. The main outcome variables included drinking measures and depressive symptoms. Analyses included all participants. Results: Mecamylamine augmentation was effective in reducing drinking outcomes particularly in nonsmokers. Symptoms of depression decreased for all participants and there was a trend indicating that this was more pronounced again for nonsmokers receiving mecamylamine. The rates of smoking decreased for all smok...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5c5f6b3088be365cc4d1ede9b6ae9bda https://doi.org/10.1080/15504263.2013.835163 Zobrazit plný text záznamu